MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma

Shailendra K. Gautam, Sushil Kumar, Andrew Cannon, Bradley Hall, Rakesh Bhatia, Mohd W Nasser, Sidharth Mahapatra, Surinder Kumar Batra, Maneesh Jain

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Introduction: Pancreatic cancer (PC) is characterized by mucin overexpression. MUC4 is the most differentially overexpressed membrane-bound mucin that plays a functional role in disease progression and therapy resistance. Area covered: We describe the clinicopathological significance of MUC4, summarize mechanisms contributing to its deregulated expression, review preclinical studies aimed at inhibiting MUC4, and discuss how MUC4 overexpression provides opportunities for developing targeted therapies. Finally, we discuss the challenges for developing MUC4-based therapeutics, and identify areas where efforts should be directed to effectively exploit MUC4 as a therapeutic target for PC. Expert opinion: Studies demonstrating that abrogation of MUC4 expression reduces proliferation and metastasis of PC cells and enhances sensitivity to therapeutic agents affirm its utility as a therapeutic target. Emerging evidence also supports the suitability of MUC4 as a potential immunotherapy target. However, these studies have been limited to in vitro, ex vivo or in vivo approaches using xenograft tumors in immunodeficient murine models. For translational relevance, MUC4-targeted therapies should be evaluated in murine models with intact immune system and accurate tumor microenvironment. Additionally, future studies evaluating MUC4 as a target for immunotherapy must entail characterization of immune response in PC patients and investigate its association with immunosuppression and survival.

Original languageEnglish (US)
Pages (from-to)657-669
Number of pages13
JournalExpert Opinion on Therapeutic Targets
Volume21
Issue number7
DOIs
StatePublished - Jul 3 2017

Fingerprint

Mucins
Tumors
Adenocarcinoma
Immune system
Pancreatic Neoplasms
Heterografts
Membranes
Immunotherapy
Therapeutics
Tumor Microenvironment
Expert Testimony
Immunosuppression
Disease Progression
Immune System
Neoplasm Metastasis
Survival
Neoplasms

Keywords

  • MUC4
  • miRNA
  • natural products
  • pancreatic cancer (PC)
  • therapeutic target
  • vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. / Gautam, Shailendra K.; Kumar, Sushil; Cannon, Andrew; Hall, Bradley; Bhatia, Rakesh; Nasser, Mohd W; Mahapatra, Sidharth; Batra, Surinder Kumar; Jain, Maneesh.

In: Expert Opinion on Therapeutic Targets, Vol. 21, No. 7, 03.07.2017, p. 657-669.

Research output: Contribution to journalReview article

Gautam, Shailendra K. ; Kumar, Sushil ; Cannon, Andrew ; Hall, Bradley ; Bhatia, Rakesh ; Nasser, Mohd W ; Mahapatra, Sidharth ; Batra, Surinder Kumar ; Jain, Maneesh. / MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. In: Expert Opinion on Therapeutic Targets. 2017 ; Vol. 21, No. 7. pp. 657-669.
@article{d18bad7b1ba04a3a98d2bf85c0136970,
title = "MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma",
abstract = "Introduction: Pancreatic cancer (PC) is characterized by mucin overexpression. MUC4 is the most differentially overexpressed membrane-bound mucin that plays a functional role in disease progression and therapy resistance. Area covered: We describe the clinicopathological significance of MUC4, summarize mechanisms contributing to its deregulated expression, review preclinical studies aimed at inhibiting MUC4, and discuss how MUC4 overexpression provides opportunities for developing targeted therapies. Finally, we discuss the challenges for developing MUC4-based therapeutics, and identify areas where efforts should be directed to effectively exploit MUC4 as a therapeutic target for PC. Expert opinion: Studies demonstrating that abrogation of MUC4 expression reduces proliferation and metastasis of PC cells and enhances sensitivity to therapeutic agents affirm its utility as a therapeutic target. Emerging evidence also supports the suitability of MUC4 as a potential immunotherapy target. However, these studies have been limited to in vitro, ex vivo or in vivo approaches using xenograft tumors in immunodeficient murine models. For translational relevance, MUC4-targeted therapies should be evaluated in murine models with intact immune system and accurate tumor microenvironment. Additionally, future studies evaluating MUC4 as a target for immunotherapy must entail characterization of immune response in PC patients and investigate its association with immunosuppression and survival.",
keywords = "MUC4, miRNA, natural products, pancreatic cancer (PC), therapeutic target, vaccine",
author = "Gautam, {Shailendra K.} and Sushil Kumar and Andrew Cannon and Bradley Hall and Rakesh Bhatia and Nasser, {Mohd W} and Sidharth Mahapatra and Batra, {Surinder Kumar} and Maneesh Jain",
year = "2017",
month = "7",
day = "3",
doi = "10.1080/14728222.2017.1323880",
language = "English (US)",
volume = "21",
pages = "657--669",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma

AU - Gautam, Shailendra K.

AU - Kumar, Sushil

AU - Cannon, Andrew

AU - Hall, Bradley

AU - Bhatia, Rakesh

AU - Nasser, Mohd W

AU - Mahapatra, Sidharth

AU - Batra, Surinder Kumar

AU - Jain, Maneesh

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Introduction: Pancreatic cancer (PC) is characterized by mucin overexpression. MUC4 is the most differentially overexpressed membrane-bound mucin that plays a functional role in disease progression and therapy resistance. Area covered: We describe the clinicopathological significance of MUC4, summarize mechanisms contributing to its deregulated expression, review preclinical studies aimed at inhibiting MUC4, and discuss how MUC4 overexpression provides opportunities for developing targeted therapies. Finally, we discuss the challenges for developing MUC4-based therapeutics, and identify areas where efforts should be directed to effectively exploit MUC4 as a therapeutic target for PC. Expert opinion: Studies demonstrating that abrogation of MUC4 expression reduces proliferation and metastasis of PC cells and enhances sensitivity to therapeutic agents affirm its utility as a therapeutic target. Emerging evidence also supports the suitability of MUC4 as a potential immunotherapy target. However, these studies have been limited to in vitro, ex vivo or in vivo approaches using xenograft tumors in immunodeficient murine models. For translational relevance, MUC4-targeted therapies should be evaluated in murine models with intact immune system and accurate tumor microenvironment. Additionally, future studies evaluating MUC4 as a target for immunotherapy must entail characterization of immune response in PC patients and investigate its association with immunosuppression and survival.

AB - Introduction: Pancreatic cancer (PC) is characterized by mucin overexpression. MUC4 is the most differentially overexpressed membrane-bound mucin that plays a functional role in disease progression and therapy resistance. Area covered: We describe the clinicopathological significance of MUC4, summarize mechanisms contributing to its deregulated expression, review preclinical studies aimed at inhibiting MUC4, and discuss how MUC4 overexpression provides opportunities for developing targeted therapies. Finally, we discuss the challenges for developing MUC4-based therapeutics, and identify areas where efforts should be directed to effectively exploit MUC4 as a therapeutic target for PC. Expert opinion: Studies demonstrating that abrogation of MUC4 expression reduces proliferation and metastasis of PC cells and enhances sensitivity to therapeutic agents affirm its utility as a therapeutic target. Emerging evidence also supports the suitability of MUC4 as a potential immunotherapy target. However, these studies have been limited to in vitro, ex vivo or in vivo approaches using xenograft tumors in immunodeficient murine models. For translational relevance, MUC4-targeted therapies should be evaluated in murine models with intact immune system and accurate tumor microenvironment. Additionally, future studies evaluating MUC4 as a target for immunotherapy must entail characterization of immune response in PC patients and investigate its association with immunosuppression and survival.

KW - MUC4

KW - miRNA

KW - natural products

KW - pancreatic cancer (PC)

KW - therapeutic target

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85020654447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020654447&partnerID=8YFLogxK

U2 - 10.1080/14728222.2017.1323880

DO - 10.1080/14728222.2017.1323880

M3 - Review article

C2 - 28460571

AN - SCOPUS:85020654447

VL - 21

SP - 657

EP - 669

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 7

ER -